Immunome, Inc. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/dc235425-04ef-4b07-9b0e-4510e9e15b71/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-224.1M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-088172 |
| FY 2024 | $-305.8M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-003302 |
| FY 2023 | $-109.5M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-004247 |
| FY 2022 | $-36.9M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-003964 |
| FY 2021 | $-25.2M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-004420 |
| FY 2020 | $-12.3M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-003493 |
| FY 2019 | $-10.3M | 2019-01-01 – 2019-12-31 | evidence 0001558370-21-003493 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).